Kronox Lab (KRONOX)

FairStock Score: 42/100 — MIXED

Score breakdown: P/E: 2/3 · ROCE: 2/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• Outstanding return ratios: ROE of 33.52% and ROCE of 43.82% indicate highly efficient capital deployment.
• Very low leverage with Debt/Equity of 0.03, providing financial stability and downside protection.
• High promoter holding of 74.21% aligns management interests with minority shareholders.
• Piotroski F-Score of 7/9 suggests solid fundamentals and good earnings quality.
• Latest quarter net margin approximately 28% (₹7 Cr profit on ₹25 Cr sales) shows strong pricing power.

Concerns

• Near-flat profit growth of 0.92% despite sales growth of 5.25% points to margin compression or rising costs.
• P/E of 17.19 and P/B of 6.28 look expensive for a business growing this slowly.
• PEG ratio of 4.12 indicates the market is pricing in significantly higher growth than delivered.
• Dividend yield of just 0.42% offers negligible income while waiting for value to be recognised.

AI Analysis

Looking at Kronox Lab, I see a business with excellent capital efficiency but little forward momentum. The company earns a return on equity of 33.52% and a ROCE of 43.82%, figures that would make any owner smile. The balance sheet is fortress-like with a debt-to-equity of just 0.03, and the promoter holding of 74.21% tells me those at the helm have skin in the game. The Piotroski score of 7 out of 9 supports the notion of a fundamentally sound enterprise. Yet as Graham would say, price is what you pay, value is what you get. At ₹129.30, the market capitalises the company at ₹445 crore, translating to a P/E of 17.19 and a P/B of 6.28. For that premium, I expect growth, but sales have risen only 5.25% and profit growth is a meagre 0.92% over the same period. The PEG ratio of 4.12 underlines that I am paying a rich multiple for very little expansion. The dividend yield of 0.42% offers scant compensation while I wait. The latest quarter, with sales of ₹25 crore and net profit of ₹7 crore, shows a strong margin, but a single quarter does not make a trend. This looks like a high-quality but slow-growing business. It may be a fine company, but at this price, the margin of safety is thin. I would wait for either a lower price or evidence that growth is re-accelerating before committing new capital.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer